Clinical Review: A Treatment for Adults with Acute Hepatic Porphyria, including Acute Intermittent Porphyria

Description

Supported by: Alnylam Pharmaceuticals

AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks of which the cardinal symptom is severe, diffuse abdominal pain. This presentation will provide a disease overview and review the clinical profile of a treatment for adults with AHP, featuring Phase 3 Study results and open-label extension data.

Presenter:

Robert Schwartz, MD, PhD